Ownership and insider activity for Onconetix, Inc. (ONCO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH).
Price
| Price | $0.66 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $6.1M | $4.3M | $1.9M | $25.8M | $4.6M | $646500 | $5.2M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $8330 | $44805 | $152524 | $35850 | $149731 | $96308 | $296866 |
| Inventory | 0 | 0 | 0 | 0 | $364052 | $64079 | $149961 |
| Total Current Assets | $6.1M | $4.6M | $3.1M | $26.3M | $5.8M | $950267 | $6.1M |
| Property, Plant & Equipment | $6931 | $15667 | $11502 | $14089 | $209196 | $182323 | $85859 |
| Goodwill | 0 | 0 | 0 | 0 | $55.7M | $27.0M | $18.5M |
| Intangible Assets | 0 | 0 | 0 | 0 | $25.4M | 0 | 0 |
| Total Assets | $6.1M | $4.8M | $3.1M | $26.3M | $87.5M | $28.2M | $24.9M |
| Accounts Payable | $18377 | $68668 | $582605 | $1.5M | $5.3M | $3.8M | $1.8M |
| Short-term Debt | 0 | 0 | 0 | 0 | $9.6M | $9.3M | 0 |
| Total Current Liabilities | $75762 | $68668 | $1.6M | $3.9M | $17.2M | $18.3M | $9.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | $118857 | 0 | $24362 |
| Total Liabilities | $82621 | $78310 | $1.6M | $3.9M | $86.1M | $18.6M | $9.2M |
| Retained Earnings | -$939870 | -$2.5M | -$6.0M | -$19.4M | -$56.8M | -$115.7M | -$131.2M |
| Total Equity | $6.0M | $4.7M | $1.4M | $22.4M | -$5.6M | $9.6M | $15.8M |
| Total Debt | 0 | 0 | 0 | 0 | $9.9M | $9.4M | $48774 |
| Net Debt | -$6.1M | -$4.3M | -$1.9M | -$25.8M | $5.3M | $8.8M | -$5.2M |
| Working Capital | $6.0M | $4.5M | $1.4M | $22.3M | -$11.4M | -$17.3M | -$3.1M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 2.21 |
Profitability
| Return on Equity | -91.95% |
| Return on Invested Capital | -59.84% |
| Return on Assets | -62.07% |
| Gross Margin | 80.40% |
| Operating Margin | -1265.55% |
| Net Margin | -1578.79% |
Related companies: AZTR · ENVB · INDP · JSPR · PTIX · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of ONCO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks